IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients (OPERA)
This study has been completed.
Sponsor:
Associations for Establishment of Evidence in Interventions
Collaborator:
Medtronic
Information provided by (Responsible Party):
Associations for Establishment of Evidence in Interventions
ClinicalTrials.gov Identifier:
NCT01325935
First received: March 29, 2011
Last updated: January 5, 2016
Last verified: January 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A prospective multicenter registry in real-world Japanese patients undergoing DAPT for three months after stenting. To assess the long-term safety of Endeavor Zotarolimus-eluting stent through noninferiority in the primary endpoint between two different continuous regimen (three and twelve months) groups of DAPT after stenting with Endeavor Zotarolimus-eluting stent in real-world Japanese patients and to examine the optimal duration of DAPT after stenting with Endeavor Zotarolimus-eluting stent. The long-term DAPT group in the present clinical study (to be appropriated from the post-marketing surveillance of Endeavor) should consist of consecutive patients undergoing DAPT for twelve months after stenting, while the short-term DAPT group (to be newly registered in the present clinical study) should consist of patients who are instructed to undergo DAPT for three months after stenting.
| Condition | Intervention | Phase |
|---|---|---|
| Coronary Artery Disease | Drug: Clopidogrel | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA) |
Resource links provided by NLM:
Further study details as provided by Associations for Establishment of Evidence in Interventions:
Primary Outcome Measures:
- NACCE (Net adverse clinical and cerebral event) [ Time Frame: 12 months ]NACCE is defined as a composite endpoint consisting of death from some causes (including cardiac death and noncardiac death), myocardial infarction (Q-wave MI and non-Q wave MI), cerebral vascular accident, and major bleeding (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding).
Secondary Outcome Measures:
- Stent thrombosis [ Time Frame: 12 months ]Incidence of stent thrombosis as per the definition by academic research council
- MACE (major adverse cardiac events) [ Time Frame: 1, 3, 6, 9 and 12 months ]Incidence of MACE at months 1, 3, 6, 9, and 12 after stenting. MACE is defined as a composite endpoint consisting of cardiac death from some causes (including cardiac and noncardiac death), MI (Q-wave MI and non-Q wave MI), TLR, and coronary artery bypass graft (CABG).
- TVR (target vessel revascularization) [ Time Frame: 9 and 12 months ]Incidence of target vessel revascularization at months 9 and 12 after stenting.
- TLR (target lesion revascularization) [ Time Frame: 9 and 12 months ]Incidence of target lesion revascularization at months 9 and 12 after stenting.
- DAPT compliance [ Time Frame: 12 months ]Duration of DAPT and patient compliance.
- Hemorrhagic complications [ Time Frame: 12 months ]Incidence of hemorrhagic complications. (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding)
| Enrollment: | 1187 |
| Study Start Date: | April 2011 |
| Study Completion Date: | December 2013 |
| Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Short-term DAPT group
1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
|
Drug: Clopidogrel
DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
|
|
No Intervention: Long-term DAPT group
1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
|
Eligibility| Ages Eligible for Study: | 20 Years to 85 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Clinical inclusion criteria
- Patient over age 20 years.
- Patient who is clinically indicated for PCI by stenting at least in one coronary lesion that is visually confirmed by coronary angiography.
- Patient who has agreed to conditions after receiving an explanation about the contents of the present clinical study and who has signed the consent form approved by the ethical review board at each study site.
- Patient who has agreed to undergo all clinical FUs listed in the present protocol.
-
Coronary angiographic inclusion criteria:
- Patient who has a > 50% occlusion or stenosis that is visually confirmed by coronary angiography in a native coronary artery > 2.5 mm in diameter and in whom the relevant coronary artery has an anatomical structure that is eligible for PCI with Endeavor Zotarolimus-eluting stent.
Exclusion Criteria:
-
Clinical exclusion criteria
- Patient over age 85 years.
- Patient with ST elevation MI who requires primary or rescue PCI and whose performance status falls under any of the exclusion criteria.
- Patient with cardiogenic shock.
- Patient who underwent stent treatment with BMS in other lesions within 6 months prior to the conduct of index PCI of the target vessel.
- Patient who has undergone some treatment with DES for coronary lesions.
- Patient who is scheduled to undergo elective surgery within 12 months after index PCI.
- Patient whose left ventricular ejection fraction (LVEF) is < 40%.
- Patient with a hemorrhagic predisposition or a history of coagulation abnormality
- Patient in whom the total number of deployed stents exceeds 4,regardless of the number of lesions and the number of affected branches.
- Patient with a verified history of CVA before stenting.
- Patient with a verified history of active peptic ulcer or upper gastrointestinal tract bleeding before Stenting.
- Patient showing impaired renal function. (serum creatinine concentration: > 1.8 mg/dL)
- Patient with known contraindications for aspirin or clopidogrel. (the physician should assess tolerability within the range of routine medical care)
- Patient with a known disorder who has a life expectancy of less than 12 months.
- Patient who is incompetent to adhere to all clinical FUs listed in the present protocol.
-
Angiographic exclusion criteria:
- Lesions located within the saphenous venin graft (SVG).
- Unprotected lesions in the left coronary trunk.
- Lesions of in-stent restenosis in previously deployed DES or BMS.
- Lesions with an anatomical structure of the coronary artery that is not eligible for treatment by the deployment of Endeavor ZES.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325935
Show 112 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325935
Show 112 Study Locations
Sponsors and Collaborators
Associations for Establishment of Evidence in Interventions
Medtronic
Investigators
| Principal Investigator: | Takaaki Isshiki, M.D. | Teikyo University |
| Principal Investigator: | Shinsuke Nanto, M.D. | Osaka University |
| Principal Investigator: | Masato Nakamura, M.D. | Toho University Ohashi Medical Center |
More Information
| Responsible Party: | Associations for Establishment of Evidence in Interventions |
| ClinicalTrials.gov Identifier: | NCT01325935 History of Changes |
| Other Study ID Numbers: |
OPERA 1.0 - AEEI |
| Study First Received: | March 29, 2011 |
| Last Updated: | January 5, 2016 |
Keywords provided by Associations for Establishment of Evidence in Interventions:
|
Coronary Artery Disease Coronary Disease Myocardial Ischemia Heart Disease Cardiovascular Disease |
Arteriosclerosis Arterial Occlusive Disease Vascular Disease Clopidogrel Platelet Aggregation Inhibitors |
Additional relevant MeSH terms:
|
Arteriosclerosis Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arterial Occlusive Diseases Vascular Diseases Aspirin Ticlopidine Clopidogrel Platelet Aggregation Inhibitors Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents |
ClinicalTrials.gov processed this record on June 23, 2017